Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Turning Point Therapeutics, Inc. TPTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
42/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$73.60
-2.5%

Turning Point Therapeutics, Inc. (TPTX) is a Biotechnology company in the Healthcare sector, currently trading at $75.49. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is TPTX = $74 (-2.5% upside).

Financials: revenue is $31M, +23.3%/yr average growth. Net income is $237M (loss), growing at -119.8%/yr. Net profit margin is -767.3% (negative). Gross margin is 100% (+100 pp trend).

Balance sheet: total debt is $6M against $954M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 21.08 (strong liquidity). Debt-to-assets is 0.6%. Total assets: $1.0B.

Analyst outlook: 8 / 14 analysts rate TPTX as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 38/100 (Fail), Income 10/100 (Fail).

$73.60
▼ 2.5% Downside
Average Price Target
The 12-month price target for Turning Point Therapeutics, Inc. is $73.60.

TPTX SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 35/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 38/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TPTX

✗
VALUE Fail
35/100
TPTX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $74, implying -2% from the current price $75. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
TPTX: +23.3%/yr revenue is, -119.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet TPTX: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 21.08 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
TPTX: Gross margin is 100% (+100 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
38/100
Analyst outlook: 8 / 14 analysts rate TPTX as buy (57%). Analyst consensus target is $74 (-2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
TPTX: Net profit margin is -767.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
Volume1.03M
Beta (1Y)-0.19
Share Statistics
EPS (TTM)-5.79
Shares Outstanding$40.84M
IPO Date2019-04-17
Employees267
CEOAthena Maria Countouriotis
Financial Highlights & Ratios
Revenue (TTM)$30.83M
Gross Profit$30.83M
EBITDA$-232.58M
Net Income$-236.55M
Operating Income$-236.55M
Total Cash$981.58M
Total Debt$5.58M
Net Debt$-422.3M
Total Assets$1B
Price / Earnings (P/E)-13
Analyst Forecast
1Y Price Target$73.60
Target High$73.60
Target Low$73.60
Upside-2.5%
Rating ConsensusBuy
Analysts Covering14
Buy 57% Hold 43% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS90041T1088

Price Chart

Track all markets on TradingView
TPTX
Turning Point Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message